The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

President Trump's $500 billion Stargate Initiative to build AI infrastructure faces blowback from his conspiracist supporters ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

By Gift Briton Global efforts for a Rift Valley fever (RVF) vaccine accelerate as South Africa’s Afrigen Biologics begins local development of mRNA vaccine.With no vaccine approved for human use yet, ...

Trump said he'd 'rather not' impose tariffs on China — a softening in stance that eased some fears over the potential for a trade war.

Traditional vaccines typically focus on the most accessible parts of viruses, which are often the rapidly mutating ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.